Molecular biology and cytogenetics

Multiple Myeloma and Related Disorders

Volumn , Issue , 2004, Pages 46-57

  Drach, Johannes ^a   Ackermann, Jutta ^a   Seidl, Sonja ^a   Kaufmann, Hannes ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27144437970     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (85)

1. Zandecki M, Lai JL, Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol 1996; 94:217-33.
2. Rajkumar SV, Fonseca R, Dewald GW, Therneau TM, Lacy MQ, Kyle RA, et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999; 113:73-7.
3. Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985; 66:380-90.
4. Weh HJ, Gutensohn K, Selbach J, Kruse R, Wacker-Backhaus G, Seeger D, et al. Karyotype in multiple myeloma and plasma cell leukemia. Eur J Cancer 1993; 29A:1269-73.
5. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995; 82:41-9.
6. Lai JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 1995; 85:2490-7.
7. Calasanz MJ, Cigudosa JC, Odero MD, Ferreira C, Ardanaz MT, Fraile A, et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes Cancer 1997; 18:84-93.
8. Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, Terre C, Lafage-Pochitaloff M, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 cases, on behalf of the Intergroupe Fancophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood 2001; 97:822-5.
9. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C, on behalf of the Groupe Francais de Cytogenetique Hematologique. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98:2229-38.
10. Drach J, Schuster J, Nowotny H, Angerler J, Rosenthal F, Fiegl M, et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 1995; 55:3854-9.
11. Cigudosa JC, Rao PH, Calasanz MJ, Odero MD, Michaeli J, Jhanwar SC, et al. Characterization of non-random chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 1998; 91:3007-13.
12. Rao PH, Cigudosa JC, Ning Y, Calasanz MJ, Iida S, Tagawa S, et al. Multicolor spectral karyotyping identifies recurring breakpoints and translocations in multiple myeloma. Blood 1998; 92:1742-8.
13. Sawyer JR, Lukacs JL, Munshi N, Desikan KR, Singhal S, Mehta J, et al. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood 1998; 92:4269-76.
14. Willis TG, Dyer MJS. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 2000; 96:808-22.
15. Bergsagel PL, Chesi MC, Nardini E, Brents LA, Kirby SL, Kuehl WH. Promiscuous translocations into IgH switch regions in multiple myeloma. Proc Natl Acad Sci USA 1996; 93:13931-6.
16. Avet-Loiseau H, Facon T, Daviet A, Godon C, Rapp MJ, Harrousseau JL, et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Cancer Res 1999; 59:4546-50.
17. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100:1417-24.
18. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100:1579-83.
19. Fonseca R, Witzig TE, Gertz MA, Kyle RA, Hoyer JD, Jalal SM, et al. Multiple myeloma and the translocation t(11;14) (q13;q32): a report on 13 cases. Br J Haematol 1998; 101:296-301.
20. Avet-Loiseau H, Li JY, Facon T, Brigaudeau C, Morineau N, Maloisel F, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998; 58: 5640-5.
21. Ronchetti D, Finelli P, Richeldi R, Baldini L, Rocci M, Viggiano L, et al. Molecular analysis of 11q13 breakpoints in multiple myeloma. Blood 1999; 93:1330-7.
22. Janssen JW, Vaandrager JW, Heuser T, Jauch A, Kluin PM, Geelene E, et al. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). Blood 2000; 95:2691-8.
23. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16:260-5.
24. Sibley K, Fenton JAL, Dring AM, Ashcroft AJ, Rawstron AC, Morgan GJ. A molecular study of the t(4;14) in multiple myeloma. Br J Haematol 2002; 118:514-20.
25. Finelli P, Fabis S, Zagano S, Baldini L, Intini D, Nobili L, et al. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double color fluorescence in situ hybridization. Blood 1999; 94:724-32.
26. Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R, et al. A novel chromosomal translocation t(4;14) (p16.3;q32) in multiple myeloma involves the fibroblast growth factor receptor 3 gene. Blood 1997; 90:4062-9.
27. Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR, et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 2000; 95:992-8.
28. Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001; 97:729-36.
29. Li Z, Zhu YX, Plowright EE, Bergsagel PL, Chesi M, Patterson B, et al. The myeloma-associated fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood 2001; 97:2413-9.
30. Pollett BP, Trudel S, Stern D, Li Z, Stewart AK. Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 (FGFR3) confers dexamthasone resistance. Blood 2002; 100:3819-21.
31. Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lack FGFR3 expression but maintain an IGH/MMSET fusion transcript. Blood 2003; 101:2374-6.
32. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Mant MJ, Belch AR, et al. In multiple myeloma t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003; 101:1520-9.
33. Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T, et al. Frequent dysregulation of the c-maf protooncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998; 91:4457-63.
34. Ho IC, Hodge MR, Rooney JW, Glimcher LH. The protooncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell 1996; 85:973-83.
35. Taniwaki M, Nishida K, Takashima T, Nakagawa H, Fujii H, Tarnaki T, et al. Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood 1994; 84:2283-90.
36. Shaughnessy J, Gabrea A, Qi Y, Brents L, Zhan F, Tian E, et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 2001; 98:217-23.
37. Iida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B, et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 1997; 17:226-30.
38. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86:4250-6.
39. Perez-Simon JA, Garcia-Sanz R, Tabernero MD, Almeida J, Gonzales M, Fernandez-Calvo J, et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 1998; 91:3366-71.
40. Zojer N, Königsberg R, Ackermann J, Fritz E, Dallinger S, Krömer E, et al. In multiple myeloma, deletion of 13q14 remains an independent adverse prognostic parameter despite its frequent detection by interphase FISH. Blood 2000; 95:1925-30.
41. Avet-Loiseau H, Li JY, Morineau N, Facon T, Brigaudeau C, Harrousseau JL, et al. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Blood 1999; 94: 2583-9.
42. Fonseca R, Oken MM, Harrington D, Bailey RJ, Van Wier SA, Henderson KJ, et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 2001; 15:981-6.
43. Shaughnessy J, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 2003; 120:44-51.
44. Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 2001; 96:1505-11.
45. Avet-Loiseau H, Daviet A, Saunier S, Bataille R. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol 2000; 111:1116-17.
46. Nomdedeu JF, Lasa A, Ubeda J, Saglio G, Bellido M, Casas S, et al. Interstitial deletions at the long arm of chromosome 13 may be as common as monosomies in multiple myeloma. A genotypic study. Haematologica 2002; 87:828-35.
47. Elnenaei MO, Hamoudi RA, Swansbury J, Gruszka-Westwood AM, Brito-Babapulle V, Matutes E, et al. Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosom Cancer 2003; 36:99-106.
48. Fonseca R, Oken MM, Greipp PR. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood 2001; 98:1271-2.
49. Le Baccon P, Leroux D, Dascalescu C, Duley S, Marais D, Esmenjaud E, et al. Novel evidence of a role for chromosome 1 pericentric heterocromatin in the pathogenesis of B-cell lymphoma and multiple myeloma. Genes Chromosomes Cancer 2001; 32:250-64.
50. Sawyer JR, Tricot G, Mattox S, Jagannath S, Barlogie B. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 1998; 91:1732-41.
51. Mugneret F, Sidaner I, Favre B, Manone L, Maynadie M, Caillot D, et al. Der(16)t(1;16)(q10;p10) in multiple myeloma: a new non-random abnormality that is frequently associated with Burkitt’s type translocations. Leukemia 1995; 9:277-81.
52. Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA 2000; 97:228-33.
53. Billadeau D, Jelinek DF, Shah N, Le Bien TW, Van Ness B. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin-6 dependent myeloma cell line ANBL6. Cancer Res 1995; 55:3640-6.
54. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993; 81:128-33.
55. Drach J, Ackermann J, Fritz E, Krömer E, Schuster R, Gisslinger H, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998; 92:802-7.
56. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature Rev Genet 2002; 3:415-28.
57. Ng MH, To KW, Lo KW, Chan S, Tsang KS, Cheng SH, et al. Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. Clin Cancer Res 2001; 7:1724-9.
58. Gonzalez M, Mateos MV, Garcia-Sanz R, Balanzategui A, Lopez-Perez R, Chillon MC, et al. De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis. Leukemia 2000; 14:183-7.
59. Mateos MV, Garcia-Sanz R, Lopez-Perez R, Moro MJ, Ocio E, Hernandez J, et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 2002; 118:1034-40.
60. Guillerm G, Gyan E, Wolowiec D, Facon T, Avet-Loiseau H, Kuliczkowski K, et al. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 2001; 98:244-6.
61. Greenhalgh CJ, Hilton DJ. Negative regulation of cytokine signaling. J Leukocyte Biol 2001; 70:348-56.
62. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003; 101:2784-8.
63. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21:103-7.
64. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, et al. Low-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000; 18:956-62.
65. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996; 14:457-60.
66. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002; 99:1745-57.
67. Drach J, Angerler J, Schuster J, Rothermund C, Thalhammer R, Haas OA, et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 1995; 86:3915-21.
68. Zandecki M, Obein V, Bernardi F, Soenen V, Flactif M, Lai JL, et al. Monoclonal gammopathy of undetermined significance: chromosomal changes are a common finding within bone marrow plasma cells. Br J Haematol 1995; 90:693-6.
69. Königsberg R, Ackermann J, Kaufmann H, Zojer N, Urbauer E, Krömer E, et al. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance. Leukemia 2000; 14:1975-9.
70. Kaufmann H, Ackermann J, Nösslinger T, Gisslinger H, Krömer E, Ludwig H, et al. Deletion of chromosome 13q is a frequent abnormality in multiple myeloma evolving from a preexisting monoclonal gammopathy of undetermined significance. Blood 2002; 100:103a.
71. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91:3-21.
72. Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B-cell lymphomas. Oncogene 2001; 20:5580-94.
73. Barlogie B, Alexanian R, Dixon D, Smith L, Smallwood L, Delasalle K. Prognostic implications of tumor cell DNA and RNA content in multiple myeloma. Blood 1985; 66:338-41.
74. Calasanz MJ, Cigudosa JC, Odero MD, Garcia-Foncillas J, Marin J, Ardana MT, et al. Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma. Br J Haematol 1997; 98:418-25.
75. Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003; 17:427-36.
76. Fassas A, Spencer J, Sawyer J, Zangari M, Choon-Kee, Anaissie E, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002; 118:1041-7.
77. Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J, et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 1998; 101:189-94.
78. Fonseca R, Harrington D, Oken MM, et al. Biological and prognostic significance of interphae fluorescence in situ hybridization detection of chromosome 13 abnormalities (∆13) in multiple myeloma. Cancer Res 2002; 62:715-20.
79. Worel N, Greinix H, Ackermann J, Kaufmann H, Urbauer E, Höcker P, et al. Deletion of chromosome 13q14 detected by FISH has prognostic impact on survival after high-dose therapy in patients with multiple myeloma. Ann Hematol 2001; 80:345-8.
80. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum 2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97:1566-71.
81. Königsberg R, Zojer N, Ackermann J, Krömer E, Kittler H, Fritz E, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 2000; 18:804-12.
82. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Bardos A, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95:4008-10.
83. Lai JL, Michaux L, Dastugue N, Vasseur F, Dau Dignon A, Facon T, et al. Cytogenetics in multiple myeloma: a multicenter study of 24 patients with t(11;14)(q13;q32) or its variant. Cancer Genet Cytogenet 1998; 104:133-8.
84. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, et al. Myeloma and the t(11;14)(q13;q32): evidence for a biologically defined unique subset of patients. Blood 2002; 99:3735-41.
85. Claudio JO, Masih-Khan E, Tang H, Goncalves J, Voralia M, Li ZH, et al. A molecular compendium of genes expressed in multiple myeloma. Blood 2002; 100:2175-86.